



06-07-06

AF
ZJW

Practitioner's Packet No. NEB-164-PUS

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Karen E. Sandman, Christopher J. Noren

Application No.: 09/937,187

Group No.: 1639

Filed: 09/21/2001

Examiner: Celsa, B.

For: Surface Display of Selenocysteine-Containing Peptides

Corres. and Mail

BOX AF

**RESPONSE UNDER
37 C.F.R. § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT OR RESPONSE AFTER FINAL REJECTION--TRANSMITTAL

1. Transmitted herewith is an amendment after final rejection (37 C.F.R. 1.116) for this application.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

G with sufficient postage as first class mail.


37 C.F.R. § 1.10*

X as "Express Mail Post Office to Addressee"

Mailing Label No. **RQ 006963807 US (mandatory)**

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (571) 273 - 8300.


Signature

Date: June 6, 2006

Leslie Goldberg

(type or print name of person certifying)

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

STATUS

2. Applicant is a small entity. A statement was already filed.

EXTENSION OF TERM

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col.1)		(Col. 2)	(Col. 3)		SMALL ENTITY
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA		ADDIT. FEE
TOTAL	7	MINUS	20	= 0	x \$	25.00 = \$ 0.00
INDEP	1	MINUS	10	= 0	x \$	100.00 = \$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					+ \$	0.00 = \$ 0.00
TOTAL						\$ 0.00
ADDIT. FEE						


No additional fee for claims is required.

FEE DEFICIENCY

5. If any additional extension and/or fee is required, charge Account No. 14-0740.

If any additional fee for claims is required, charge Account No. 14-0740.

Date: June 6, 2006



Harriet M. Strimpel, D.Phil.
Registration No. 37,008
New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938-2723
978-380-7373
Customer No. 28986



Docket # 2006-04-PUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Sandman et al. EXAMINER: Lundgren

SERIAL NO.: 09/937,187 GROUP: 1639


FILED: September 9, 2001

FOR: Surface Display of Selenocysteine-Containing Peptides

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Express Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage in an Express Mail Envelope Label No. EQ 006963869 US addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 6, 2006.


Leslie Goldberg

Sir:

Supplemental Amendment

This Supplemental Amendment is being filed following a telephone conference with the Examiner on June 5, 2006.

The amendments to claims presented here are based on the assumption that Applicant's response filed on May 19, 2006 has not been entered. A listing of the claims is presented on pages 3-5 of this paper. Applicant has cancelled claims 40-58 and renumbered claims 40-58 as 59-77. Changes to the specification appear on page 6. The

Sandman et al.
09/937,187
Page 2

Remarks section begins on page 7 of this paper. The Summary section appears on page 8.